drugset / Trial / NCT00199901
Study of NY-ESO-1 ISCOMATRIX® in Patients With High-risk, Resected Melanoma
Phase 2
Completed
111 enrolled
Ludwig Institute for Cancer Research
Institute of Cancer Research, United Kingdom · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this trial is to assess whether treatment with NY-ESO-1 ISCOMATRIX® vaccine improves outcomes for people with Malignant Melanoma which has been removed, but is at high risk of relapse.
Timeline
- Start
- 2005-09
- Primary completion
- 2008-12
- Completion
- 2011-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | NY-ESO-1 ISCOMATRIX® | Vaccine | 100 ug | Intramuscular |
| Comparator | NY-ESO-1 ISCOMATRIX® | Vaccine | 120 ug | Intramuscular |
| Comparator | Iscomatrix adjuvant | Unknown | 120 ug | Intramuscular |